Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial
Authors:
Top Cited Papers
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 148 (1) , 164-172.e9
Abstract
No abstract availableKeywords
Funding Information
- BioCryst Pharmaceuticals, Inc
- At Harvard Medical School
- Harvard Catalyst/The Harvard Clinical and Translational Science Center
- National Center for Research Resources
- National Center for Advancing Translational Sciences, National Institutes of Health
This publication has 17 references indexed in Scilit:
- Burden of Illness in Hereditary Angioedema: A Conceptual ModelActa Dermato-Venereologica, 2015
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012
- Development and construct validation of the angioedema quality of life questionnaireAllergy, 2012
- Pathophysiology of Hereditary AngioedemaAmerican Journal of Rhinology & Allergy, 2011
- Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapyJournal of Allergy and Clinical Immunology, 2010
- The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depressionAllergy and Asthma Proceedings, 2010
- Hereditary AngioedemaNew England Journal of Medicine, 2008
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006
- Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth and Quality of Life Outcomes, 2004
- Treatment of Hereditary Angioedema with DanazolNew England Journal of Medicine, 1976